Berkman Charles S
SEC CIK 1392266 · EDGAR
BoughtSold
Most active insiders at OABI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FOEHR MATTHEW W | Pres, CEO, Dir | — | $143.5K |
| 2 | HIGGINS JOHN L | Dir | $107.7K | — |
| 3 | GUSTAFSON KURT A | CFO, Executive VP, Fin | — | $84.7K |
| 4 | Berkman Charles S | CLO | — | $54.9K |
| 5 | Crouse Steven C. | Dir | — | — |
| 6 | Gotwals Philip J | Dir | — | — |
| 7 | Cochran Jennifer R. | Dir | — | — |
| 8 | Bertozzi Carolyn R | Dir | — | — |
| 9 | Love Steven | Dir | — | — |
Transactions 36
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-07 20:23 | 2026-04-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | $0.00 | +13.5K | 406.2K | +3% | $0 |
| D | 2026-04-07 20:23 | 2026-04-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $1.49 | -7,157 | 399.1K | -2% | -$10.7K |
| D | 2026-02-18 | 2026-02-18 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | $0.00 | +18.8K | 402.4K | +5% | $0 |
| D | 2026-02-18 | 2026-02-18 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $1.71 | -9,673 | 392.7K | -2% | -$16.5K |
| D | 2026-02-17 | 2026-02-17 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $1.70 | -6,990 | 383.6K | -2% | -$11.9K |
| D | 2026-02-17 | 2026-02-16 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | $0.00 | +13.5K | 390.6K | +4% | $0 |
| D | 2025-12-09 | 2025-12-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | $0.00 | +15.6K | 385.1K | +4% | $0 |
| D | 2025-12-09 | 2025-12-08 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $1.96 | -8,044 | 377.1K | -2% | -$15.8K |
| D | 2025-04-07 | 2025-04-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $2.00 | -7,206 | 363.2K | -2% | -$14.4K |
| D | 2025-04-07 | 2025-04-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | $0.00 | +13.5K | 370.4K | +4% | $0 |
| DM | 2025-02-19 | 2025-02-15+ | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | — | +29.2K | 372.3K | +8% | — |
| DM | 2025-02-19 | 2025-02-18+ | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $3.68 | -15.5K | 364.1K | -4% | -$56.9K |
| 2025-01-22 | 2025-01-17 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | A - Grant | $0.00 | +45.3K | 368.7K | +14% | $0 | |
| 2025-01-22 | 2025-01-21 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale | $3.24 | -25.5K | 343.2K | -7% | -$82.6K | |
| D | 2024-12-10 | 2024-12-09 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $4.13 | -8,022 | 323.4K | -2% | -$33.1K |
| D | 2024-12-10 | 2024-12-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | — | +15.6K | 331.4K | +5% | — |
| A | 2024-04-23 | 2022-11-01 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | A - Grant | — | +366.5K | 305.4K | New | — |
| D | 2024-04-09 | 2024-04-08 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | S - Sale+OE | $5.27 | -6,954 | 292.6K | -2% | -$36.6K |
| D | 2024-04-09 | 2024-04-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | — | +13.5K | 299.6K | +5% | — |
| DM | 2024-02-20 | 2024-02-15 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | F - Tax | $5.54 | -7,609 | 282.4K | -3% | -$42.2K |
| DM | 2024-02-20 | 2024-02-15 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | — | +21.3K | 287.9K | +8% | — |
| D | 2024-01-03 | 2024-01-02 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | — | +17.6K | 279.5K | +7% | — |
| D | 2024-01-03 | 2024-01-02 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | F - Tax | $6.25 | -7,195 | 272.3K | -3% | -$45.0K |
| D | 2023-12-11 | 2023-12-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | F - Tax | $4.85 | -5,403 | 262.0K | -2% | -$26.2K |
| D | 2023-12-11 | 2023-12-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | M - OptEx | — | +15.6K | 267.4K | +6% | — |
| D | 2023-04-11 | 2023-04-07 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | A - Grant | $0.00 | +40.6K | 414.6K | +11% | $0 |
| M | 2023-02-17 | 2023-02-15 | OABI | OmniAb, Inc. | Berkman Charles S | CLO | F - Tax | $3.80 | -9,543 | 376.1K | -2% | -$36.3K |
| 2023-01-05 | 2023-01-03 | OABI | OmniAb, Inc. | Berkman Charles S | See Remarks | A - Grant | $0.00 | +46.9K | 383.5K | +14% | $0 | |
| 2022-12-30 | 2022-12-28 | OABI | OmniAb, Inc. | Berkman Charles S | See Remarks | F - Tax | $3.66 | -6,518 | 336.6K | -2% | -$23.9K | |
| 2022-12-05 | 2022-12-01 | OABI | OmniAb, Inc. | Berkman Charles S | See Remarks | F - Tax | $3.35 | -10.6K | 343.1K | -3% | -$35.4K | |
| D | 2022-11-03 | 2022-11-01 | OABI | OmniAb, Inc. | Berkman Charles S | See Remarks | A - Grant | — | +353.7K | 353.7K | New | — |
| D | 2022-11-03 | 2022-11-01 | LGND | LIGAND PHARMACEUTICALS INC | Berkman Charles S | Former Executive Off | D - Sale to Iss | — | -11.9K | 23.8K | -33% | — |
| 2022-06-14 | 2022-06-10 | LGND | LIGAND PHARMACEUTICALS INC | Berkman Charles S | SVP, Gen. Counsel, Sec | A - Grant | $0.00 | +5,375 | 35.8K | +18% | $0 | |
| M | 2022-02-16 | 2022-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Berkman Charles S | SVP, Gen. Counsel, Sec | F - Tax | $123.68 | -1,578 | 31.0K | -5% | -$195.2K |
| M | 2022-01-28 | 2022-01-26 | LGND | LIGAND PHARMACEUTICALS INC | Berkman Charles S | SVP, Gen. Counsel, Sec | F - Tax | $113.68 | -2,156 | 33.3K | -6% | -$245.1K |
| M | 2022-01-28 | 2022-01-26 | LGND | LIGAND PHARMACEUTICALS INC | Berkman Charles S | SVP, Gen. Counsel, Sec | A - Grant | $0.00 | +6,237 | 30.3K | +26% | $0 |
Purchase Sale Sale after option exercise All abbreviations